MDR-TB occurs when a strain of TB bacteria becomes resistant to two or more “first-line” antibiotic drugs prescribed to combat standard TB. According to the Ministry of Health and Child Welfare, cases of MDR-TB nearly doubled from 156 in 2011 to 244 cases in 2013. This was despite the fact that notifications for ordinary TB drastically declined from 47,000 in 2010 to 38,367 in 2012.
26 January 2015 | Inter Press Service
At a press conference convened by the AIDS Healthcare Foundation Ukraine today, a group of patients, experts and activists delivered a strong message that the country is experiencing a preventable tuberculosis (TB) outbreak this year due to the failure of state procurements to obtain essential medications. Activists urged that immediate measures be taken to address the crisis, including distributing needed medical supplies, creating transparent procurement systems and assessing the effectiveness of TB treatment for each patient in accordance to international standards.
15 January 2015 | AIDS Healthcare Foundation press release
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria.
12 December 2014 | PR Newswire
The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.
11 December 2014 | The Guardian
A nine-month treatment regiment for multidrug-resistant tuberculosis (MDR-TB) appears to be as effective as a 12-month regiment, according to data from two new studies being presented today at the 45th World Conference on Lung Health in Barcelona, Spain.
31 October 2014 | International Union Against Tuberculosis and Lung Disease
A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB
29 October 2014 | World Health Organization
In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.
28 October 2014 | Institute of Tropical Medicine
UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects.
UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.
27 October 2014 | UNITAID
World Health Organisation says spread of hardier strains of TB across former USSR nations is of ‘critical concern’.
22 October 2014 | The Guardian
The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.
21 October 2014 | Business Day